000279287 001__ 279287
000279287 005__ 20210129221028.0
000279287 0247_ $$2doi$$a10.1007/s11095-015-1791-2
000279287 0247_ $$2ISSN$$a0724-8741
000279287 0247_ $$2ISSN$$a1573-904X
000279287 0247_ $$2WOS$$aWOS:000368073300007
000279287 0247_ $$2altmetric$$aaltmetric:4808080
000279287 0247_ $$2pmid$$apmid:26381279
000279287 037__ $$aFZJ-2015-07302
000279287 041__ $$aEnglish
000279287 082__ $$a610
000279287 1001_ $$0P:(DE-HGF)0$$aLeithold, Leonie H. E.$$b0
000279287 245__ $$aPharmacokinetic Properties of a Novel d-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers
000279287 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2016
000279287 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1453737283_6240
000279287 3367_ $$2DataCite$$aOutput Types/Journal article
000279287 3367_ $$00$$2EndNote$$aJournal Article
000279287 3367_ $$2BibTeX$$aARTICLE
000279287 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000279287 3367_ $$2DRIVER$$aarticle
000279287 520__ $$aPURPOSE:It has been shown that amyloid β (Aβ) oligomers play an important role in the pathology of Alzheimer's disease (AD). D3, a peptide consisting solely of D-enantiomeric amino acid residues, was developed to specifically eliminate Aβ oligomers and is therapeutically active in transgenic AD mice. D-peptides have several advantages over L-peptides, but little is known about their pharmacokinetic potential in vivo. Here, we analysed the pharmacokinetic properties of RD2, a rationally designed and potent D3 derivative.METHODS:The pharmacokinetic analysis was performed using 3H-RD2 after administration via several routes in mice. The time dependent amount of radiolabelled RD2 was measured in plasma and several organ homogenates by liquid scintillation counting. Furthermore, binding to plasma proteins was estimated.RESULTS:RD2 penetrates into the brain, where it is thought to implement its therapeutic function. All administration routes result in a maximal brain concentration per dose (Cmax/D) of 0.06 (μg/g)/(mg/kg) with brain/plasma ratios ranging between 0.7 and 1.0. RD2 shows a small elimination constant and a long terminal half-life in plasma of more than 2 days. It also exhibits high bioavailability after i.p., s.c. or p.o. administration.CONCLUSIONS:These excellent pharmacokinetic properties confirm that RD2 is a very promising drug candidate for AD.KEYWORDS:Alzheimer’s disease; D-enantiomer; peptide; pharmacokinetics; preclinical
000279287 536__ $$0G:(DE-HGF)POF3-553$$a553 - Physical Basis of Diseases (POF3-553)$$cPOF3-553$$fPOF III$$x0
000279287 588__ $$aDataset connected to CrossRef
000279287 7001_ $$0P:(DE-Juel1)145884$$aJiang, Nan$$b1$$ufzj
000279287 7001_ $$0P:(DE-Juel1)164337$$aPost, Julia$$b2$$ufzj
000279287 7001_ $$0P:(DE-Juel1)162487$$aZiehm, Tamar$$b3$$ufzj
000279287 7001_ $$0P:(DE-Juel1)166069$$aSchartmann, Elena$$b4$$ufzj
000279287 7001_ $$0P:(DE-Juel1)159137$$aKutzsche, Janine$$b5$$ufzj
000279287 7001_ $$0P:(DE-HGF)0$$aShah, N. Jon$$b6
000279287 7001_ $$0P:(DE-HGF)0$$aBreitkreutz, Jörg$$b7
000279287 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b8$$ufzj
000279287 7001_ $$0P:(DE-Juel1)144347$$aWilluweit, Antje$$b9$$ufzj
000279287 7001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b10$$eCorresponding author$$ufzj
000279287 773__ $$0PERI:(DE-600)2036232-8$$a10.1007/s11095-015-1791-2$$n2$$p328-36$$tPharmaceutical research$$v33$$x1573-904X$$y2016
000279287 8564_ $$uhttps://juser.fz-juelich.de/record/279287/files/Pharmacokinetic%20Properties%20of%20a%20Novel%20d-Peptide%20Developed%20to%20be%20Therapeutically%20Active%20Against%20Toxic%20%CE%B2-Amyloid%20Oligomers.pdf$$yRestricted
000279287 8564_ $$uhttps://juser.fz-juelich.de/record/279287/files/Pharmacokinetic%20Properties%20of%20a%20Novel%20d-Peptide%20Developed%20to%20be%20Therapeutically%20Active%20Against%20Toxic%20%CE%B2-Amyloid%20Oligomers.pdf?subformat=pdfa$$xpdfa$$yRestricted
000279287 909CO $$ooai:juser.fz-juelich.de:279287$$pVDB
000279287 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145884$$aForschungszentrum Jülich GmbH$$b1$$kFZJ
000279287 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)164337$$aForschungszentrum Jülich GmbH$$b2$$kFZJ
000279287 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)162487$$aForschungszentrum Jülich GmbH$$b3$$kFZJ
000279287 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166069$$aForschungszentrum Jülich GmbH$$b4$$kFZJ
000279287 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159137$$aForschungszentrum Jülich GmbH$$b5$$kFZJ
000279287 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich GmbH$$b8$$kFZJ
000279287 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144347$$aForschungszentrum Jülich GmbH$$b9$$kFZJ
000279287 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich GmbH$$b10$$kFZJ
000279287 9131_ $$0G:(DE-HGF)POF3-553$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lBioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vPhysical Basis of Diseases$$x0
000279287 9141_ $$y2016
000279287 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000279287 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000279287 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARM RES-DORDR : 2014
000279287 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000279287 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000279287 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000279287 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000279287 915__ $$0StatID:(DE-HGF)0550$$2StatID$$aNo Authors Fulltext
000279287 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000279287 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000279287 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000279287 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000279287 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000279287 920__ $$lyes
000279287 9201_ $$0I:(DE-Juel1)ICS-6-20110106$$kICS-6$$lStrukturbiochemie $$x0
000279287 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000279287 980__ $$ajournal
000279287 980__ $$aVDB
000279287 980__ $$aUNRESTRICTED
000279287 980__ $$aI:(DE-Juel1)ICS-6-20110106
000279287 980__ $$aI:(DE-Juel1)INM-4-20090406
000279287 981__ $$aI:(DE-Juel1)IBI-7-20200312
000279287 981__ $$aI:(DE-Juel1)INM-4-20090406